<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932681</url>
  </required_header>
  <id_info>
    <org_study_id>2021/CHU/05</org_study_id>
    <nct_id>NCT04932681</nct_id>
  </id_info>
  <brief_title>Use of Medicinal Plants and Other Alternative and Complementary Medicines by Patients With Cancer in Reunion Island</brief_title>
  <acronym>CAMUCRI</acronym>
  <official_title>Evaluation of the Use of Medicinal Plants and Other Alternative and Complementary Medicines by Patients With Cancer in Reunion Island</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APLAMEDOM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory, observational and cross-sectional study with the aim of describing the use of&#xD;
      plants for medicinal purposes (and other Complementary and Alternative Medicine) and&#xD;
      identifying the determinants of this use. The methodology envisaged is mixed with an&#xD;
      exploratory design combining qualitative (interviews) and quantitative techniques&#xD;
      (questionnaires).&#xD;
&#xD;
      To knowledge of investigators, no study has been carried out in Reunion Island on the use of&#xD;
      plants and other alternative and complementary medicines among cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Use of herbal medicine</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of patients using herbal medicine (from the patient's perspective) among cancer patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barriers of dialogue between patient and practionner</measure>
    <time_frame>Day 1</time_frame>
    <description>Interviews between patient and interviewer will help to extract the barriers limiting patient/practitioner dialogue on Complementary and Alternative Medicine use from patient and practitioner perspectives</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Information on Complementary and Alternative Medicine</measure>
    <time_frame>Day 1</time_frame>
    <description>Interviews between patient and interviewer will help to find out expectations about the need for information on Complementary and Alternative Medicine use from the patient's perspective and from the practitioner's perspective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improving questionnaire after the practionners' focus group</measure>
    <time_frame>Day 1</time_frame>
    <description>A practionners' focus group will be organised after the interviews to review the feedbacks and opinions on the questionnaire to improve the questionnaire for the quantitative part of the study</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Qualitative group</arm_group_label>
    <description>Interview about the use of Complementary and Alternative Medecine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quantitative group</arm_group_label>
    <description>Questionnaire about the use of Complementary and Alternative Medecine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancer linving in the Reunion Island&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Living in Reunion Island&#xD;
&#xD;
          -  Suffering from cancer (solid tumors, hematological malignancies)&#xD;
&#xD;
          -  Able to answer a questionnaire&#xD;
&#xD;
          -  Patient who does not oppose to the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person of legal age under guardianship or under legal protection&#xD;
&#xD;
          -  Persons who do not understand French or Reunionese Creole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florent DRAPEAU, PharmD</last_name>
    <phone>02 62 35 90 00</phone>
    <email>florent.drapeau@chu-reunion.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia BERLY</last_name>
    <phone>02 62 90 62 86</phone>
    <email>laetitia.berly@chu-reunion.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <contact>
      <last_name>Florent DRAPEAU, PharmD</last_name>
      <phone>02 62 35 90 00</phone>
      <email>florent.drapeau@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia ZUNIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Clotilde</name>
      <address>
        <city>Sainte-Clotilde</city>
        <zip>97490</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine MORICEAU, PharmD</last_name>
      <email>antoine.moriceau@clinifutur.net</email>
    </contact>
    <investigator>
      <last_name>Gilles BAUMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Réunion</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

